Repligen Corporation (RGEN) Rating Reiterated by Jefferies Group LLC
Repligen Corporation (NASDAQ:RGEN)‘s stock had its “hold” rating reiterated by stock analysts at Jefferies Group LLC in a research report issued on Thursday. They presently have a $40.00 price target on the biotechnology company’s stock. Jefferies Group LLC’s price objective indicates a potential downside of 9.75% from the company’s current price.
RGEN has been the topic of several other reports. Zacks Investment Research raised shares of Repligen Corporation from a “hold” rating to a “buy” rating and set a $46.00 price objective on the stock in a report on Saturday, August 12th. BidaskClub lowered shares of Repligen Corporation from a “strong-buy” rating to a “buy” rating in a report on Wednesday, June 14th. William Blair initiated coverage on shares of Repligen Corporation in a report on Friday, July 21st. They set an “outperform” rating on the stock. TheStreet raised shares of Repligen Corporation from a “c+” rating to a “b-” rating in a report on Friday, August 11th. Finally, Janney Montgomery Scott lifted their price objective on shares of Repligen Corporation from $42.00 to $47.00 in a report on Friday, June 23rd. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $42.00.
Shares of Repligen Corporation (NASDAQ RGEN) opened at 44.32 on Thursday. Repligen Corporation has a 12 month low of $26.16 and a 12 month high of $46.81. The stock has a 50 day moving average price of $42.01 and a 200-day moving average price of $38.70. The company has a market capitalization of $1.66 billion, a PE ratio of 86.73 and a beta of 1.21.
Repligen Corporation (NASDAQ:RGEN) last issued its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.15 by $0.05. The company had revenue of $32.40 million for the quarter, compared to analyst estimates of $31.72 million. Repligen Corporation had a net margin of 15.61% and a return on equity of 9.90%. Repligen Corporation’s revenue was up 11.0% compared to the same quarter last year. During the same period last year, the company posted $0.16 earnings per share. Analysts forecast that Repligen Corporation will post $0.59 EPS for the current year.
TRADEMARK VIOLATION WARNING: This article was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.watchlistnews.com/repligen-corporation-rgen-rating-reiterated-by-jefferies-group-llc/1565698.html.
Institutional investors and hedge funds have recently made changes to their positions in the business. Quantbot Technologies LP acquired a new stake in Repligen Corporation in the second quarter valued at approximately $120,000. Ameritas Investment Partners Inc. acquired a new stake in Repligen Corporation in the first quarter valued at approximately $103,000. Oppenheimer Asset Management Inc. acquired a new stake in Repligen Corporation in the second quarter valued at approximately $123,000. Victory Capital Management Inc. boosted its stake in Repligen Corporation by 76.6% in the first quarter. Victory Capital Management Inc. now owns 3,400 shares of the biotechnology company’s stock valued at $120,000 after acquiring an additional 1,475 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in Repligen Corporation by 31.9% in the first quarter. JPMorgan Chase & Co. now owns 3,755 shares of the biotechnology company’s stock valued at $133,000 after acquiring an additional 908 shares in the last quarter. Institutional investors own 97.91% of the company’s stock.
About Repligen Corporation
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.
Receive News & Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.